Introduction
GnRH agonist-analogues were first reported to be effective in suppressing pituitarygonadal function in children with central precocious puberty in 1981 (1). However, it is only in recent years that the long-term outcomes regarding final height and reproductive competency after therapy have been documented by several groups from around the world (2-5). During our own ongoing longitudinal studies, some 200 children with early pubertal development have been evaluated, with approximately two-thirds going on to receive GnRH analogue therapy, some for as long as 9 years. More than half of these children have now re-entered puberty following the discontinuation of GnRH analogue administration. This review will addressthe experience from our longitudinal studies with respect to: suppression of pubertal development during GnRH analogue administration; the reactivation of puberty following the discontinuation of therapy; and the impact of gonadal sex steroid suppression on long-term growth and final height. 
Pituitary
Gonadotroph Desensitization: Impact on Pubertal Development Following the discovery and characterization of GnRH, the decade of the 1970s was marked by tremendous advances in our understanding of the physiology of hypothalamicpituitary regulation as well as in our ability to translate this new information into novel therapeutic approaches. Physiologic studies revealed that hormone secretion from the anterior pituitary occurred in a pulsatile fashion and that the pituitary gonadotroph required intermittent stimulation by GnRH to achieve this physiologic pattern of hormone release (6). Continuous stimulation by GnRH resulted not in high level, ongoing gonadotropin secretion but rather an eventual decline in LH and FSH secretion or desensitization of the pituitary response. On a different front, several laboratories sought to modify the native GnRH decapeptide to create more potent and long-lasting analogues. Employing similar strategies of peptide design, several GnRH agonist analogues were synthesized and subsequently employed in clinical trials (7) . It was soon recognized that these GnRH analogues, by virtue of their increased potency and prolonged duration of action were capable of achieving continuous receptor occupancy on the pituitary gonadotrope and thus of inducing pituitary desensitization.
With increased clinical experience with these agents, especially in children with precocious puberty, it became clear that there were important differences among therapeutic regimens of GnRH agonist administration in their ability to induce complete pituitary-gonadal suppression. The potency, dose, and route of administration of the regimen employed must all be considered in designing the appropriate regimen, but more importantly, the impact of that regimen must be monitored in each patient to ensure that the desired degree of suppression has been attained (7, 8) .
Given that the appropriate consideration is given to issues of potency and pharmacokinetics, the chronic administration of a GnRH agonist results in virtually complete blockade of the reproductive axis at the level of the pituitary (cf. Fig. 1 ). When this degree of pituitary gonadotropin suppression is achieved, dramatic changes in pubertal development result. The changes in sexual maturation which are induced by suppressing LH, FSH, and estradiol include a return to prepubertal appearances of the uterus and ovaries on ultrasound (9), a halt or regression in breast development (cf. Fig. 2 ), and the cessation of menses, with the caveat that an initial episode of bleeding may follow the fall in estrogen that comes within the first few weeks of GnRH analogue administration.
Despite consistent suppression of the pituitary-gonadal axis, we and others have shown that adrenarche, as indexed by serum levels of dehydroepiandrosterone-sulfate, progresses during GnRHa administration (10). As shown in Figure 2 , the clinical manifestations of this can be dramatic since rising levels of adrenal androgens may result in the new appearance of pubic hair during the same period that breast development undergoes striking regression. We have utilized this ability to block gonadarche selectively to dissect the impact of adrenarche in our patients with CPP and have reported a modest but significant impact of adrenarche on the rates of skeletal maturation during GnRHa administration (10). In ongoing studies, the ability to block gonadal steroids selectively allows us to test whether changes in adrenal sex steroid secretion are correlated with the increases in both lean body mass and body fat which accompany normal development in the latter stages of childhood.
There are a host of questions which remain to be explored regarding the biologic consequences of adrenarche, many of which are the subject of longitudinal study in our patients in whom gonadal steroids are "clamped" at prepubertal levels.
Resumption of Puberty following
Discontinuation of Therapy Following the discontinuation of chronic GnRHa administration, pubertal secretion of LH and FSH is restored. In patients whom we have monitored as outpatients, urinary gonadotropin excretion has increased after years of virtually complete suppression within weeks following the discontinuation of daily GnRHa injections. Evaluations performed six months following the discontinuation of pituitary desensitization have consistently shown a return of pubertal gonadotropin secretion which has been accompanied by increases in gonadal size and serum levels of gonadal sex steroids in both sexes.
In adolescent girls with idiopathic CPP , menarche has followed the discontinuation of GnRHa therapy by approximately one year, although the range has extended from a few months to more than three years (2,11). Menstrual cycles lengths became increasingly regular and have been associated with higher rates of ovulation as girls were evaluated for longer periods post-menarche.
In our follow-up study of girls with CPP following the discontinuation of therapy, ovulatory rates were comparable to those previously documented in adolescent controls whose onset of pubertal development had been normally timed (11, 12) .
While the patient numbers are far smaller, it is important to note that pubertal maturation in the male also appears to proceed normally when GnRHa is discontinued. However, there has been one patient in our study who has failed to resume puberty following GnRHa therapy and his case makes some important points, for his was not a problem with irreversibility of GnRHainduced suppression.
Rather, he had precocious puberty in the setting of an optic tract tumor for which he received a full course of cranial irradiation.
In 
Impact
of Gonadal Suppression on Long-term Growth and Final Height Left untreated, pubertal levels of sex steroids in young children with CPP result in dramatic growth spurts and tall stature in childhood, but premature fusion of the epiphyses shortens the growth period resulting in final height which fall short of genetic expectations. Figure 3 , an individual patient's height and height velocity chart, underscores these points as well as demonstrating the impact of suppressing gonadal sex steroids with GnRHa. While growth velocities decrease with the withdrawal of sex steroids, the delay in epiphyseal fusion which also accompanies gonadal suppression results in a prolonged period of growth. Thus, predicted final heights have increased in most patients with CPP, averaging 2-3cm for each year of therapy in our study and others (13, 14) . However, the changes in predicted height have been quite variable among patients. Some patients have gained up to 20cm while others' have exhibited either no change or small decreases in predicted heights during long-term therapy.
This variability comes, at least in part, from the wide range of chronological ages and bone ages with which patients have initiated gonadal steroid suppression. In very young patients with precocity, growth rates have returned to and remained in the normal prepubertal range over many years of GnRHa administration while gonadal suppression begun in patients at older CAs and BAs exhibit growth rates that often are well below prepubertal norms (ie. <4cm/year) (15) . While worrisome to the clinician/investigator, these slow growth rates are not unexpected in many such patients given their advanced skeletal maturation (eg. girls with TW BA 13 years). In fact, predicted heights characteristically increase in this group of patients, since sustained, albeit slow, growth exceeds expectations based on bone age. While, patients with with "early pubertal" bone ages (eg. girls with TWBA 10-12 years) have exhibited the most variable changes in predicted heights early on. However, these patients often display consistent increases after 1-2 years of therapy and thus typically exceed their pretherapy prediction with long-term therapy (16) .
Given these variable patterns of growth and skeletal maturation, long-term longitudinal follow-up has been a necessity to the com- tial, was significantly younger upon starting therapy than those patients whose growth is completed and whose height deficit was only partially erased with therapy. Whether the actual final heights in this younger group now being followed during the return of active puberty will reach current predictions must await ongoing studies.
In addition, a group of patients who began GnRHa therapy at even younger ages is just approaching the discontinuation of treatment at this time. The natural history of CPP would suggest that these patients would exhibit the greatest deficit in adult statue if sex steroid secretion was left unchecked.
If their current predictions prove accurate, they also will attain final heights in keeping with their genetic potential. Thus a comprehensive understanding of the impact of long-term gonadal sex steroid suppression on final height across a broad developmental spec-trum must await future data stemming from these younger cohorts.
The variation in final heights correlated with the underlying diagnosis, the duration of therapy, and the age and bone age at which therapy was begun.
In addition, as is the case with most if not all growth disorders, there remains a significant correlation with target height even in children with abnormal growth patterns. Figure 4 reviews the experience from our study regarding the ages at which patients started and stopped therapy, achieved menarche, and attained their final heights. To date, most patients with CPP who have completed this "journey" have tended to be those who began GnRHa at older chronological ages and bone ages. It is in this somewhat skewed subset of patients that final height data is available. Those CPP patients who have achieved their final height significantly exceeded the prediction made prior to therapy, but did not reach their genetic target. Even at this stage of our experience with these agents, several important questions remain. Continued follow-up is still required to determine whether or not patients whose puberty is suppressed at earlier stages reach their genetic potential. With their data in hand, we will be better equipped to address additional questions about the use of GnRH agonists in the therapy of growth disorders including, "Will growth hormone in combination with GnRHa provide additional benefit in some patients with CPP?" and "Will suppressing a normallytimed puberty result in increased adult stature in other growth disorders (eg. GH deficiency)?" While preliminary data looks promising, there is not short-cut to the longitudinal studies that are required to address these important issues. Now that GnRH agonists have been utilized in children for more than a decade, their track record of safety is excellent. Most impor- 
